EMMA Emmaus Life Sciences, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 822370 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.0%
TTM net income YoY-77.9%
TTM EPS YoY-100.0%
Revenue 3-yr CAGR-18.2%
Net income 3-yr CAGR—
Margins
Gross margin93.6%
Operating margin29.3%
Net margin-38.8%
FCF margin—
EBITDA margin29.7%
Returns
ROE—
ROA-30.3%
ROIC (approx.)—
Asset turnover0.78x
Leverage & solvency
Liabilities / assets504.3%
Debt / equity—
Current ratio0.09x
Interest coverage0.57x
Cash quality & payout
Operating cash flow / net income-0.66x
Accruals ratio-50.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $12.45M | $16.65M | $29.60M | $18.39M | $20.61M |
| Cost of revenue | $857,000 | $1.20M | $1.34M | $2.59M | $3.31M |
| Gross profit | $11.60M | $15.45M | $28.25M | $15.80M | $17.30M |
| R&D expense | $313,000 | $657,000 | $1.19M | $1.73M | $4.11M |
| SG&A expense | $8.18M | $10.69M | $14.89M | $13.17M | $13.44M |
| Operating income | $231,000 | -$1.89M | $3.54M | -$6.59M | -$6.13M |
| Interest expense | $7.13M | $5.49M | $7.38M | $5.01M | $3.10M |
| Pretax income | -$7.48M | -$6.42M | -$3.79M | -$10.56M | -$15.92M |
| Income tax | $9,000 | $29,000 | -$59,000 | $60,000 | $25,000 |
| Net income | -$7.49M | -$6.45M | -$3.73M | -$10.62M | -$15.95M |
| EBITDA | $270,000 | -$1.87M | $3.57M | -$6.53M | -$6.07M |
| EPS (basic) | -0.12 | -0.10 | -0.07 | -0.21 | -0.32 |
| EPS (diluted) | -0.12 | -0.10 | -0.07 | -0.21 | -0.32 |
| Weighted avg. shares (diluted) | 64.04M | 63.23M | 53.11M | 49.44M | 49.25M |
| Balance sheet | |||||
| Cash & equivalents | $2.13M | $1.39M | $2.55M | $2.02M | $2.28M |
| Receivables | $2.80M | $2.62M | $5.52M | $375,000 | $1.04M |
| Inventory | $1.55M | $1.64M | $1.71M | $2.38M | $4.39M |
| Current assets | $7.75M | $6.77M | $11.51M | $6.29M | $9.09M |
| PP&E, net | $113,000 | $46,000 | $59,000 | $75,000 | $147,000 |
| Total assets | $21.44M | $23.60M | $35.18M | $48.23M | $56.73M |
| Current liabilities | $69.07M | $63.55M | $61.51M | $54.32M | $37.10M |
| Long-term debt | $27.13M | $28.96M | $30.56M | $30.42M | $22.34M |
| Total debt | $27.13M | $28.96M | $30.56M | $30.42M | $22.34M |
| Total liabilities | $85.04M | $80.08M | $82.94M | $82.32M | $78.18M |
| Shareholders' equity | -$63.61M | -$56.48M | -$47.76M | -$34.09M | -$21.45M |
| Net debt | $25.00M | $27.58M | $28.02M | $28.40M | $20.06M |
| Shares outstanding | 70.19M | 63.87M | 61.85M | 49.58M | 49.31M |
| Cash flow statement | |||||
| Operating cash flow | -$11,000 | -$2.29M | -$1.50M | -$5.07M | -$1.25M |
| Capital expenditure | $1,000 | $12,000 | $17,000 | $26,000 | $73,000 |
| Free cash flow | -$12,000 | -$2.30M | -$1.52M | -$5.10M | -$1.33M |
| Investing cash flow | $2.17M | $2.50M | -$432,000 | -$2.39M | -$6.38M |
| Financing cash flow | -$1.43M | -$1.35M | $2.48M | $7.23M | $7.41M |
| Depreciation & amortization | $39,000 | $22,000 | $32,000 | $53,000 | $59,000 |
| Stock-based compensation | $25,000 | $256,000 | $1.26M | $16,000 | $553,000 |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.